Spain, April 17 -- Spain based Sothis Servicios Tecnologicos has secured contract from Consejeria de Salud y Consumo for Computer support services Microcomputer service assistance and support for user... Read More
PATNA, April 17 -- The Bihar government has stepped up efforts to operationalise 19 proposed Kendriya Vidyalayas across the state, with chief secretary Pratyaya Amrit directing all departments and dis... Read More
New Delhi, April 17 -- Acclaimed sitarist Rishab Rikhiram Sharma met Delhi Chief Minister Rekha Gupta ahead of the much-anticipated finale of his landmark 'Sitar for Mental Health India Tour 2026' in ... Read More
Singapore, April 17 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combi... Read More
Singapore, April 17 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More
Singapore, April 17 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More
Singapore, April 17 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More
Singapore, April 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More
Singapore, April 17 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More
Singapore, April 17 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More